Drug intelligence / Profile preview

Onco-2

Development stage: Preclinical
Lead developer: Interdict Bio
Modality: Small Molecules

Overview

Onco-2 is a preclinical drug candidate being developed by Interdict Bio for the treatment of solid tumors and hematological cancers. Currently in the hit-to-lead phase of development, the program is part of Interdict Bio's discovery pipeline, which utilizes a proprietary platform to develop 'interdictors'—small molecules designed to modulate protein function by targeting protein-protein interfaces. While the specific molecular target for Onco-2 has not been publicly disclosed, the program represents one of the company's early-stage efforts in oncology alongside its lead MYC-targeting program.

Targets

Ribosomal peptidyl transferase center–nascent MYC polypeptide complex

Beyond the preview

Go deeper on Onco-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Onco-2.

Explore the full profile